ArticlePloS one2025
Intelligent glucose management in hospitalized patients: Short-term glucose and adverse events prediction.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trustworthy AI for personalized glycemic control: a systematic review and critical appraisal of multimodal forecasting and safety-critical closed-loop control.Reviews in endocrine & metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of blood glucose in hospitalized patients is confined to retrospective interventions, preventing healthcare professionals from predicting patients' blood glucose levels and potential adverse events in advance. This study employs a deep learning model, specifically a Stacked Attention-Gated Recurrent Unit (SA-GRU) network, to forecast short-term blood glucose (BG) levels and predict adverse events in hospitalized patients, assisting clinicians in making clinical decisions. We collect continuous glucose monitoring(CGM) data from 196 hospitalized patients with type 2 diabetes, and by constructing and training this deep learning model, we predict blood glucose levels and adverse events.The model's predictions are then compared with the actual CGM data, and different evaluation metrics are used to assess the predictions of blood glucose levels and adverse events. Additionally, experiments were conducted on another publicly available type 2 diabetes dataset. On our collected data, for the 30-minute prediction, the root mean square error (RMSE) and mean absolute relative difference (MARD) of blood glucose are 4.27 ± 0.31 mg/dL and 1.77% ± 0.08%, respectively, with an adverse event classification accuracy of 98.57% ± 0.11%. For the 60-minute prediction, the RMSE and MARD of blood glucose are 10.46 ± 0.55 mg/dL and 4.59% ± 0.22%, respectively, with an adverse event classification accuracy of 95.74% ± 0.33%. Similar positive results were obtained on another publicly available dataset. The proposed model demonstrates accurate predictions for blood glucose values and adverse events in the next 30 and 60 minutes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.